Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 13/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31558461 | 0.92 | BACE1 (0.43) | BACE1SIRT3ALKP2RX3 | |
| SCHEMBL30766002 | 0.88 | USP2 (0.37) | BACE1ALKKDM4EUSP2ALDH1A1 | |
| SCHEMBL30766008 | 0.86 | BACE1 (0.43) | BACE1ALKP2RX3 | |
| SCHEMBL30765957 | 0.80 | ALDH1A1 (0.38) | KDM4EUSP2ALDH1A1P2RX3 | |
| SCHEMBL30765510 | 0.80 | L3MBTL1 (0.41) | SIRT3ALDH1A1GAA | |
| SCHEMBL30765995 | 0.79 | ALDH1A1 (0.37) | KDM4EUSP2ALDH1A1 | |
| SCHEMBL30765941 | 0.79 | ALDH1A1 (0.37) | KDM4EUSP2ALDH1A1GAAP2RX3 | |
| SCHEMBL30765931 | 0.79 | ALDH1A1 (0.37) | KDM4EUSP2ALDH1A1GAAP2RX3 | |
| SCHEMBL30765991 | 0.79 | ELANE (0.42) | KDM4EALDH1A1 | |
| SCHEMBL30765977 | 0.78 | GAA (0.51) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |